Global Candida Infections Drugs Market – Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Candida Infections Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Candida Infections Drugs Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2022 –2029
Diagram Market Size (Base Year)
USD 14.42 Billion
Diagram Market Size (Forecast Year)
USD 19.73 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Candida Infections Drugs Market, By Type (Athletes Foot, Oral Thrush, Vaginal Yeast Infection, Nail Fungus, Jock Itch, Diaper Rash), Drug Type (Azoles, Echinocandins, Other Drugs), Treatment (Antibiotics, Benzodiazepines, Contraceptives and Hormone Replacement Therapy), Dosage Form (Gels and Creams, Lozenges, Tablets, Liquids, Sprays, Powders, Ointments), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.

Candida Infections Drugs Market

Candida Infections Drugs Market Analysis and Size

The global candida infections drugs market is expected to witness significant growth during the forecast period. The growing prevalence rate of fungal infections such as candidiasis and aspergillosis is one of the key factors propelling the market. With respect to its treatment, the increasing popularity of over-the-counter (OTC) drugs such as econazole, ketoconazole, miconazole,clotrimazole, and amorolfine, many patients are found to be taking OTC drugs to obtain a prescription from a health professional.

Data Bridge Market Research analyses a growth rate in the global candida infections drugs market in the forecast period 2022-2029. The expected CAGR of the global candida infections drugs market tends to be around 4.00% in the mentioned forecast period. The market was valued at USD 14.42 billion in 2021, and it would grow up to USD 19.73 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Candida Infections Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (Athletes Foot, Oral Thrush, Vaginal Yeast Infection, Nail Fungus, Jock Itch, Diaper Rash), Drug Type (Azoles, Echinocandins, Other Drugs), Treatment (Antibiotics, Benzodiazepines, Contraceptives and Hormone Replacement Therapy), Dosage Form (Gels and Creams, Lozenges, Tablets, Liquids, Sprays, Powders, Ointments), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Amgen Inc. (U.S.)

Market Opportunities

  • Increasing Demand for Retail Pharmacies
  • Higher Drug Launches and Innovations

Market Definition

Candida infection is a yeast infection where the skin acts as a host organism, and the infection multiplies and grows with the period. Candida albicans are the most common species of this infection. Candida normally lives on the skin and inside the body, such as the throat, gut, mouth, and vagina, without causing problems. It can cause infections if it grows out of control or enters deep into the body.

Global Candida Infections Drugs Market Dynamics

Drivers

  • Higher Demand for Azoles

Synthetic azoles and semi-synthetic compounds are widely used for more fungal infections and infections. These drugs are used to treat thrush, candidiasis, aspergillosis, yeast infection, tinea versicolor, athlete's foot, ringworm, fungal infections, systemic mycosis, and seborrheic dermatitis. The azole group provides a broad spectrum of activity and improved safety standards. These medications have fewer side effects, worse drug interactions, and improved absorption and distribution properties. Thus, it acts as a major driver in market growth.

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by the rise in the number of research and development activities. This will provide beneficial opportunities for the global candida infection drugs market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government funds research and development (R&D) initiatives.

Opportunities

  • Higher Drug Launches and Innovations

The development and innovation of many potential drugs support the competitiveness of the pharmaceutical market. The sale of both established agents and newly launched antifungal agents is important. For instance, in 2019, Mayne Pharma announced the launch of the TOLSURA 65mg capsule in the U.S. TOLSURA is a formulation of itraconazole that has been shown to treat fungal infections of the system, including histoplasmosis, blastomycosis, aspergillosis, and others. Therefore, all of these factors are projected to contribute to partial growth in the forecast period.  

  • Increasing Demand for Retail Pharmacies

The increase in the number of drugs used for global candida infections delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily available.

Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to perform these treatments could reduce the growth of the global candida infections drugs market over a forecast period.

  • Unavailability of Appropriate Treatments

To treat conditions that are rare, many a time, all treatments are not available, especially in underdeveloped countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in hospitals and clinics. Thus, it hampers market growth.

This global candida infections drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global candida infections drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Candida Infections Drugs Market Scope

The global candida infections drugs market is segmented on the basis of type, drug type, treatment, dosage form, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Athletes Foot
  • Oral Thrush
  • Vaginal Yeast Infection
  • Nail Fungus
  • Jock Itch
  • Diaper Rash 

Drug Type

  • Azoles
  • Echinocandins
  • Other Drugs

Treatment

  • Antibiotics
  • Benzodiazepines
  • Contraceptives
  • Hormone Replacement Therapy

Dosage Form

  • Gels and Creams
  • Lozenges
  • Tablets
  • Liquids
  • Sprays
  • Powders
  • Ointments

End-Users

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

Candida Infections Drugs Market Regional Analysis/Insights

The global candida infections drugs market is analysed and market size insights and trends are provided by type, drug type, treatment, dosage form,end-user, distribution channel as referenced above.

The major countries covered in the global candida infections drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the highest investment in healthcare and awareness.

Asia-Pacific is considered to have the most lucrative period due to the developing healthcare facilities, large number of generic manufacturers, and rise in government initiatives

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Candida Infections Drugs Market Share Analysis

The global candida infections drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global candida infections drugs market.

Key players operating in the global candida infections drugs market include:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Merck & Co., Inc. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Lilly (U.S.)
  • Amgen Inc. (U.S.)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Candida Infections Drugs Market is projected to grow at a CAGR of 4.00% during the forecast period by 2029.
The future market value of the Candida Infections Drugs Market is expected to reach USD 19.73 billion by 2029.
The major players in the Candida Infections Drugs Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), etc.
The countries covered in the Candida Infections Drugs Market are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, etc.